22 mayo 2018 año - FDA convened a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss the new drug application for buprenorphine sublingual spray, submitted by INSYS Development Company, Inc., for the treatment of moderate-to-severe acute pain where the use of an opioid analgesic isappropriate.
Añadido al timeline:
fecha:
22 mayo 2018 año
Ahora mismo
~ 7 years and 5 months ago